Key result
Balloon pulmonary angioplasty is predominantly used to treat chronic thromboembolic pulmonary hypertension in Japan, whereas in Europe women undergo pulmonary endarterectomy less frequently than men.
Balloon pulmonary angioplasty is an important treatment option for CTEPH, with regional and gender differences in its utilization that are being further investigated in ongoing registries.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare major vessel pulmonary vascular disease that is characterised by fibrotic obstructions deriving from an organised clot. Recent advances in treatments for CTEPH have significantly improved outcomes. Apart from classical surgical pulmonary endarterectomy, balloon pulmonary angioplasty (BPA) and vasodilator drugs that were tested in randomised controlled trials of non-operable patients are now available. In Europe, CTEPH affects males and females equally. In the first European CTEPH Registry, women with CTEPH underwent pulmonary endarterectomy less frequently than men, especially at low-volume centres. In Japan, CTEPH is more common in females and is predominantly treated by BPA. More data on gender-specific outcomes are expected from the results of the International BPA Registry (NCT03245268).
No takes yet. Share an insight, caveat, or question.
Iréne Lang (2023) conducted a review in Chronic thromboembolic pulmonary hypertension (CTEPH). Balloon pulmonary angioplasty (BPA) was evaluated. Balloon pulmonary angioplasty is predominantly used to treat chronic thromboembolic pulmonary hypertension in Japan, whereas in Europe women undergo pulmonary endarterectomy less frequently than men.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: